Wall Street Zen lowered shares of Celcuity (NASDAQ:CELC – Free Report) from a sell rating to a strong sell rating in a report issued on Saturday morning.
Several other brokerages have also issued reports on CELC. Citigroup reaffirmed an “outperform” rating on shares of Celcuity in a research note on Wednesday, July 15th. Wells Fargo & Company reduced their price objective on Celcuity from $183.00 to $166.00 and set an “overweight” rating on the stock in a research report on Wednesday, June 3rd. Guggenheim reissued a “buy” rating on shares of Celcuity in a report on Wednesday, June 3rd. Stifel Nicolaus dropped their target price on Celcuity from $175.00 to $150.00 and set a “buy” rating for the company in a research report on Friday. Finally, HC Wainwright restated a “buy” rating and issued a $155.00 target price on shares of Celcuity in a research report on Friday. Ten research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $154.55.
Celcuity Stock Performance
Celcuity (NASDAQ:CELC – Get Free Report) last announced its earnings results on Thursday, August 13th. The company reported ($1.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.16) by ($0.28). As a group, equities research analysts predict that Celcuity will post -3.76 EPS for the current fiscal year.
Institutional Investors Weigh In On Celcuity
Several institutional investors have recently added to or reduced their stakes in CELC. Avoro Capital Advisors LLC bought a new stake in Celcuity in the 4th quarter worth $310,302,000. Bank of America Corp DE bought a new position in shares of Celcuity during the second quarter valued at about $153,928,000. NEA Management Company LLC raised its stake in shares of Celcuity by 64.9% during the fourth quarter. NEA Management Company LLC now owns 3,535,561 shares of the company’s stock valued at $352,637,000 after acquiring an additional 1,391,300 shares during the last quarter. State Street Corp raised its stake in shares of Celcuity by 126.6% during the fourth quarter. State Street Corp now owns 1,637,687 shares of the company’s stock valued at $163,343,000 after acquiring an additional 914,887 shares during the last quarter. Finally, UBS Group AG boosted its holdings in shares of Celcuity by 910.1% during the third quarter. UBS Group AG now owns 854,483 shares of the company’s stock worth $42,211,000 after purchasing an additional 769,891 shares during the period. Hedge funds and other institutional investors own 63.33% of the company’s stock.
Celcuity Company Profile
Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.
Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.
Featured Articles
- Five stocks we like better than Celcuity
- Commodities Are Booming, But These 3 ETFs Tell Different Stories
- 3 Active ETFs Making Big Moves in August
- This ETF Is Outperforming by Avoiding the S&P 500’s Biggest Problem
- Birkenstock Beats the Skeptics—But Not on EPS
Receive News & Ratings for Celcuity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celcuity and related companies with MarketBeat.com's FREE daily email newsletter.
